Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review

Cancer Treatment Reviews

Volumn 40, Issue 1, 2014, Pages 86-92

  Charehbili, A ^a   Fontein, D B Y ^a   Kroep, J R ^a   Liefers, G J ^a   Mieog, J S D ^a   Nortier, J W R ^a   Van de Velde, C J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Elderly; Endocrine therapy; Neoadjuvant; Surgery

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CELECOXIB; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; GOSERELIN; LETROZOLE; PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SIZE; CANCER SURGERY; COMPARATIVE EFFECTIVENESS; FEMALE; HUMAN; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

BREAST CANCER; ELDERLY; ENDOCRINE THERAPY; NEOADJUVANT; SURGERY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CELL SURFACE; TREATMENT OUTCOME;

EID: 84887120377     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.06.001     Document Type: Review

References (47)

1. Beatson C.T. On treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896, 2:162-165.
2. Mieog J.S., van der Hage J.A., van de Velde C.J. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 2007, 94(10):1189-1200.
3. St.Gallen Consensus Panel 2013. Update of the internationally acclaimed interdisciplinary expert St. Gallen consensus panel on the optimal primary treatment of early breast cancer in press.
4. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 1988, 319(26):1681-1692.
5. Colleoni M., Bagnardi V., Rotmensz N., et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 2009 Jul, 116(2):359-369.
6. Joerger M., Thurlimann B. Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev Anticancer Ther 2013, 13(2):165-178.
7. Llombart-Cussac A., Guerrero A., Galan A., et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Clin Transl Oncol 2012 Feb, 14(2):125-131.
8. Hille U., Soergel P., Langer F., Schippert C., Makowski L., Hillemanns P. Aromatase inhibitors as solely treatment in postmenopausal breast cancer patients. Breast J 2012 Mar, 18(2):145-150.
9. Dixon J.M., Renshaw L., Dixon J., Thomas J. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy. Breast Cancer Res Treat 2011, 130(3):871-877.
10. Olson J.A., Budd G.T., Carey L.A., et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg 2009, 208(5):906-914.
11. Krainick-Strobel U.E., Lichtenegger W., Wallwiener D., et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer 2008, 8:62.
12. Dixon J.M., Renshaw L., Macaskill E.J., et al. Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat 2009, 113(1):145-151.
13. Torrisi R., Bagnardi V., Pruneri G., et al. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer 2007, 97(6):802-808.
14. Salmon R.J., Alran S., Malka I., et al. Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment. Am J Clin Oncol 2006, 29(4):385-388.
15. Miller W.R., White S., Dixon J.M., Murray J., Renshaw L., Anderson T.J. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer 2006, 94(7):1051-1056.
16. Cappelletti V., Celio L., Bajetta E., et al. Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Endocr Relat Cancer 2004, 11(4):761-770.
17. Ciatto S., Cirillo A., Confortini M., Cardillo C.L. Tamoxifen as primary treatment of breast cancer in elderly patients. Neoplasma 1996, 43(1):43-45.
18. McDonald P.J., Carpenter R., Royle G.T., Taylor I. Poor response of breast cancer to tamoxifen. Postgrad Med J 1990, 66(782):1029-1031.
19. Milla-Santos A., Milla L., Calvo N., et al. Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer. Anticancer Res 2004, 24(2C):1315-1318.
20. Cataliotti L., Buzdar A.U., Noguchi S., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 2006, 106(10):2095-2103.
21. Eiermann W., Paepke S., Appfelstaedt J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001, 12(11):1527-1532.
22. Masuda N., Sagara Y., Kinoshita T., et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol 2012, 13(4):345-352.
23. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005, 23(22):5108-5116.
24. Ellis M.J., Suman V.J., Hoog J., et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2-3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 2011, 29(17):2342-2349.
25. Chow L.W., Yip A.Y., Loo W.T., Lam C.K., Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008, 111(1-2):13-17.
26. Baselga J., Semiglazov V., Van D.P., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27(16):2630-2637.
27. Dixon J.M., Love C.D., Bellamy C.O., et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001, 66(3):191-199.
28. Dixon J.M., Renshaw L., Bellamy C., Stuart M., Hoctin-Boes G., Miller W.R. The effects of neoadjuvant anastrozole (arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 2000, 6(6):2229-2235.
29. Alba E., Calvo L., Albanell J., et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol 2012, 23(12):3069-3074.
30. Generali D., Buffa F.M., Berruti A., et al. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol 2009, 27(2):227-234.
31. Semiglazov V.F., Semiglazov V.V., Dashyan G.A., et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007, 110(2):244-254.
32. Thomas J.S., Julian H.S., Green R.V., Cameron D.A., Dixon M.J. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. Histopathology 2007, 51(2):219-226.
33. Hind D., Wyld L., Beverley C.B., Reed M.W. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women 70years plus. Cochrane Database Syst Rev 2006, 1:CD004272.
34. clinicaltrials.gov/show/NCT01622361. Neo-Adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient with Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer (NEST). 2013.
35. Petit T., Wilt M., Velten M., et al. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer. Breast Cancer Res Treat 2010, 124(2):387-391.
36. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20(8):1319-1329.
37. van de Water W., Fontein D.B., van Nes J.G., et al. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis. Eur J Cancer 2013, 49(2):297-304.
38. Katz A., Saad E.D., Porter P., Pusztai L. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol 2007, 8(1):55-62.
39. Purushotham A., Pinder S., Cariati M., Harries M., Goldhirsch A. Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast?. J Clin Oncol 2010, 28(22):3552-3554.
40. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001, 19(18):3808-3816.
41. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47(1):207-214.
42. Hayward J.L., Carbone P.P., Heusen J.C., Kumaoka S., Segaloff A., Rubens R.D. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977, 35(3):292-298.
43. Dowsett M., Smith I.E., Ebbs S.R., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007, 99(2):167-170.
44. Dowsett M., Smith I.E., Ebbs S.R., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007, 99(2):167-170.
45. Ellis M., Suman V., McCall L., et al. Neoadjuvant aromatase inhibitor trial: a phase 2 study of triage to chemotherapy Based on 2-4weeks Ki67 level. Cancer Res. 2012, 72:PD07-01.
46. Goncalves R., Ma C., Luo J., Suman V., Ellis M.J. Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. Nat Rev Clin Oncol 2012, 9(4):223-229.
47. Ellis M.J., Tao Y., Luo J., et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008 Oct 1, 100(19):1380-1388.